Skip to main content
TipRanks
Go Ultimate75% OFF

Anuh Pharma Limited (ANUHPHR) AI Stock Analysis

1 Followers
IN:ANUHPHR

Anuh Pharma Limited

(NSE:ANUHPHR)

Select Model
Rating:61Neutral
Price Target:INR 92.00â–²(11.49% Upside)
Action:reiterated
Date:10/31/26

The score is primarily held back by weaker FY2026 fundamentals—margin compression and especially negative operating/free cash flow—despite the strong, near-zero debt balance sheet and solid revenue growth. Technicals are moderately supportive with the stock trading above major moving averages, while valuation is reasonable but not distinctly attractive.

Positive Factors
Revenue GrowthStrong revenue expansion indicates that demand for Anuh Pharma’s API portfolio has been growing over time. Continued sales growth can support operating scale, strengthen its role as a supplier to formulation companies, and provide a foundation for improved earnings if profitability stabilizes.
Negative Factors
Negative Cash GenerationNegative operating and free cash flow indicates that reported earnings are not currently converting reliably into cash. If this persists, it could constrain internally funded growth, increase reliance on working-capital management, and reduce flexibility despite the company’s low debt.

Anuh Pharma Limited (ANUHPHR) vs. iShares MSCI India ETF (INDA)

-20%-10%0%10%20%30%IN:ANUHPHR+4.29%INDA-5.79%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 8.26B
Dividend Yield
1.82%
Average Volume (3M)
17.82K
Price to Earnings (P/E)
17.3
Beta (1Y)
0.50
Revenue Growth
6.62%
EPS Growth
53.57%
Country
India
Employees
323
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Anuh Pharma Limited Business Overview & Revenue Model

Company Description

Anuh Pharma Ltd. is an Indian enterprise specializing in the manufacturing and distribution of bulk drugs and various chemical compounds. The company provides a comprehensive selection of active pharmaceutical ingredients (APIs), encompassing macroli...

How the Company Makes Money

Anuh Pharma Limited primarily makes money by selling active pharmaceutical ingredients (APIs) and related bulk drug products to customers such as pharmaceutical formulation companies and other drug manufacturers. Revenue is recognized from the sale o...

Anuh Pharma Limited Financial Statement Overview

Summary

Revenue growth is strong and the balance sheet is exceptionally low-debt (high financial flexibility), but FY2026 profitability weakened (gross and net margin compression) and cash generation deteriorated sharply with negative operating and free cash flow, raising near-term cash-conversion concerns.

Income Statement

62Positive

Balance Sheet

88Very Positive

Cash Flow

34Negative
Financial statement breakdown
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue3.84B7.72B6.62B6.47B5.27B4.87B
Gross Profit910.30M1.34B1.62B1.60B1.26B1.09B
EBITDA329.27M660.76M703.64M872.47M573.89M520.43M
Net Income200.69M410.46M473.52M600.58M361.80M305.61M
Balance Sheet
Total Assets5.09B5.57B5.07B4.46B4.05B3.47B
Cash, Cash Equivalents and Short-Term Investments135.33M531.61M734.15M622.56M530.77M252.65M
Total Debt2.27M583.00K108.86M26.93M9.07M42.23M
Total Liabilities1.82B2.05B1.81B1.54B1.64B1.33B
Stockholders Equity3.27B3.52B3.26B2.91B2.41B2.14B
Cash Flow
Free Cash Flow-58.52M-108.42M169.79M79.08M523.51M272.49M
Operating Cash Flow121.88M-29.73M371.25M129.25M539.02M288.64M
Investing Cash Flow162.28M172.97M-199.09M9.18M-434.84M-78.17M
Financing Cash Flow-294.46M-258.22M-48.60M-85.68M-122.87M-194.49M

Anuh Pharma Limited Technical Analysis

Technical Analysis SentimentNeutral
Last Price82.52

Price Trends

50DMA85.53Negative
100DMA81.88Positive
200DMA79.07Positive

Market Momentum

MACD-0.42Negative
RSI48.96Neutral
STOCH31.27Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ANUHPHR, the sentiment is Neutral. The current price of 82.52 is above the 20-day moving average (MA) of 81.66, below the 50-day MA of 85.53, and above the 200-day MA of 79.07, indicating a neutral trend. The MACD of -0.42 indicates Negative momentum. The RSI at 48.96 is Neutral, neither overbought nor oversold. The STOCH value of 31.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ANUHPHR.

Anuh Pharma Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:ANUHPHR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:KILITCHIN:KILITCH63NeutralINR 7.53B30.88――13.87%-17.80%
IN:ANUHPHRIN:ANUHPHR61NeutralINR 8.27B17.30―1.82%6.62%53.57%
IN:ZIMLABIN:ZIMLAB60NeutralINR 7.60B263.30――13.14%-60.77%
IN:WANBURYIN:WANBURY56NeutralINR 6.77B12.69――7.45%-6.56%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:ALBERTDAVDIN:ALBERTDAVD54NeutralINR 4.48B15.52―0.63%19.69%―
IN:SIGACHIIN:SIGACHI47NeutralINR 10.88B43.65―0.35%-3.07%―

* General Sector Average

Performance Comparison

-50%0%50%100%IN:ANUHPHRIN:ALBERTDAVDIN:KILITCHIN:SIGACHIIN:WANBURYIN:ZIMLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:ANUHPHR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:ANUHPHRAnuh Pharma Limited82.523.434.34%
IN:ALBERTDAVDAlbert David Ltd785.00-16.43-2.05%
IN:KILITCHKilitch Drugs (India) Limited215.4037.8321.30%
IN:SIGACHISigachi Industries Limited28.47-6.53-18.65%
IN:WANBURYWanbury Limited193.65-39.25-16.85%
IN:ZIMLABZim Laboratories Ltd.141.7067.7991.72%

Anuh Pharma Limited Corporate Events

Anuh Pharma Challenges Income Tax Demand Order for FY 2018-19

Sep 18, 2026

Anuh Pharma Limited has received a demand order from the Income Tax Department for the assessment year 2018-19, citing disallowance of certain deductions and raising a tax demand of Rs 9,93,206. The company plans to appeal the order before the Commis...

Anuh Pharma Clears Board Reappointments, Auditor Mandate and Governance Overhaul

Aug 14, 2026

Anuh Pharma Limited has approved several management and governance changes at its 66th Annual General Meeting, including the reappointment of non-executive non-independent directors Bipin Nemchand Shah and Arun Lalchand Todarwal. The meeting also con...

Anuh Pharma Shareholders Clear Board Reappointments and Governance Updates

Aug 14, 2026

Anuh Pharma Limited has reported that shareholders at its 66th Annual General Meeting approved the reappointment of two non-executive non-independent directors and the cost auditor for the financial year ending March 2027. The company also approved r...

Anuh Pharma Publishes Q1 FY27 Unaudited Results in Newspapers

Aug 9, 2026

Anuh Pharma Limited has published newspaper notices announcing the availability of its unaudited financial results for the quarter ended 30 June 2026. The results were carried in the Financial Express (English) and Mumbai Lakshdeep (Marathi) on 9 Aug...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026